Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice

NCT02962765 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT02962765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02962765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice
Lead sponsor
Octapharma
Phase
Observational
Overall status
Completed
Start date
January 31, 2015
Completion date
August 20, 2020
Enrollment
80 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a